SB0222 • 2026

Right to Try Amendments

Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor: Sen. Wilson, Chris H.
Last action: 2026-03-18
Official status: Governor Signed
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Right to Try Amendments

This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.

What This Bill Does

This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-03-18 Lieutenant Governor's office for filing
Governor Signed
2026-03-13 Senate Secretary
Senate/ received enrolled bill from Printing
2026-03-13 Executive Branch - Governor
Senate/ to Governor
2026-03-11 Senate Secretary
Enrolled Bill Returned to House or Senate
2026-03-11 Senate Secretary
Senate/ enrolled bill to Printing
2026-03-06 Legislative Research and General Counsel / Enrolling
Bill Received from Senate for Enrolling
2026-03-06 Legislative Research and General Counsel / Enrolling
Draft of Enrolled Bill Prepared
2026-03-06 Senate President
Senate/ received from House
2026-03-06 Legislative Research and General Counsel / Enrolling
Senate/ signed by President/ sent for enrolling
2026-03-05 House 3rd Reading Calendar for Senate bills
House/ 3rd reading
2026-03-05 House Speaker
House/ passed 3rd reading
2026-03-05 Senate President
House/ signed by Speaker/ returned to Senate
2026-03-05 Senate President
House/ to Senate
2026-03-02 House 3rd Reading Calendar for Senate bills
House/ 2nd reading
2026-03-02 House Health and Human Services Committee
House/ committee report favorable
2026-02-27 House Health and Human Services Committee
House Comm - Favorable Recommendation
2026-02-25 House Health and Human Services Committee
House/ to standing committee
2026-02-24 House Rules Committee
House/ 1st reading (Introduced)
2026-02-23 Clerk of the House
House/ received from Senate
2026-02-23 Legislative Fiscal Analyst
LFA/ bill assigned to staff for fiscal analysis for SB0222S02
2026-02-23 Legislative Fiscal Agency
LFA/ bill sent to agencies for fiscal input for SB0222S02
2026-02-23 Released
LFA/ fiscal note publicly available for SB0222S02
2026-02-23 Version Sponsor
LFA/ fiscal note sent to sponsor for SB0222S02
2026-02-23 Senate 3rd Reading Calendar
Senate/ 3rd reading
2026-02-23 Senate 3rd Reading Calendar
Senate/ circled
2026-02-23 Clerk of the House
Senate/ passed 3rd reading
2026-02-23 Senate 3rd Reading Calendar
Senate/ substituted
2026-02-23 Clerk of the House
Senate/ to House
2026-02-23 Senate 3rd Reading Calendar
Senate/ uncircled
2026-02-20 Senate 2nd Reading Calendar
Senate/ 2nd reading
2026-02-20 Senate 3rd Reading Calendar
Senate/ passed 2nd reading
2026-02-20 Senate 2nd Reading Calendar
Senate/ substituted
2026-02-19 Released
LFA/ fiscal note publicly available for SB0222S01
2026-02-18 Version Sponsor
LFA/ fiscal note sent to sponsor for SB0222S01
2026-02-17 Legislative Fiscal Analyst
LFA/ bill assigned to staff for fiscal analysis for SB0222S01
2026-02-17 Legislative Fiscal Agency
LFA/ bill sent to agencies for fiscal input for SB0222S01
2026-02-04 Senate Health and Human Services Committee
Senate/ committee report favorable
2026-02-04 Senate 2nd Reading Calendar
Senate/ placed on 2nd Reading Calendar
2026-02-03 Senate Health and Human Services Committee
Senate Comm - Favorable Recommendation
2026-02-02 Released
LFA/ fiscal note publicly available for SB0222
2026-02-02 Version Sponsor
LFA/ fiscal note sent to sponsor for SB0222
2026-02-02 Senate Rules Committee
Senate/ received fiscal note from Fiscal Analyst
2026-02-02 Senate Health and Human Services Committee
Senate/ to standing committee
2026-01-30 Senate Rules Committee
Senate/ 1st reading (Introduced)
2026-01-29 Legislative Research and General Counsel
Bill Numbered but not Distributed
2026-01-29 Legislative Fiscal Analyst
LFA/ bill assigned to staff for fiscal analysis for SB0222
2026-01-29 Legislative Fiscal Agency
LFA/ bill sent to agencies for fiscal input for SB0222
2026-01-29 Legislative Research and General Counsel
Numbered Bill Publicly Distributed
2026-01-29 Waiting for Introduction in the Senate
Senate/ received bill from Legislative Research

Official Summary Text

This bill amends provisions related to when a patient may obtain and use investigational drugs and devices to treat an illness.

Current Bill Text

Read the full stored bill text

8
58-85-102
58-85-107
0
Right to Try Amendments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Chris H. Wilson
House Sponsor: Tyler Clancy
LONG TITLE
General Description:
This bill amends provisions related to when a patient may obtain and use investigational
drugs and devices to treat an illness.
Highlighted Provisions:
This bill:
allows a patient to obtain an investigational drug or device in additional circumstances;
amends the definition regarding the forms a medicine may take; and
creates a reporting requirement for manufacturers.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
58-85-102
, as last amended by Laws of Utah 2025, Chapter 114
ENACTS:
58-85-107
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section
58-85-102
is amended to read:
58-85-102
. Definitions.
As used in this chapter:
(1)
"Eligible illness" means a condition of a patient that:
(a)
as determined by a physician, presents a substantial and severely debilitating or
life-threatening risk to the patient; and
(b)
presents the patient, after the patient has explored conventional therapy options, with
no treatment option that is satisfactory or comparable to treatment with an
investigational drug or investigational device.
(2)
"Eligible patient" means an individual who has been diagnosed with a terminal illness
or
eligible illness
by a physician.
(2)
(3)
"Insurer" means the same as that term is defined in Section
31A-1-301
.
(3)
(4)
"Investigational device" means a device that:
(a)
meets the definition of "investigational device" in 21 C.F.R. Sec. 812.3;
and
(b)
has successfully completed the United States Food and Drug Administration Phase 1
testing for an investigational device described in 21 C.F.R. Part 812
.
; and
(c)
if used to treat an eligible illness, is currently undergoing an investigation, as defined
in 21 C.F.R. Sec. 812.3, that complies with all applicable requirements for the
investigation in accordance with 21 C.F.R. Part 812.
(4)
(5)
"Investigational drug" means a drug that:
(a)
meets the definition of "investigational new drug" in 21 C.F.R. Sec. 312.3;
and
(b)
has successfully completed the United States Food and Drug Administration Phase 1
testing for an investigational new drug described in 21 C.F.R. Part 312
.
; and
(c)
if used to treat an eligible illness, is currently undergoing a clinical investigation, as
defined in 21 C.F.R. Sec. 312.3, that complies with all applicable requirements for
the clinical investigation in accordance with 21 C.F.R. Part 312.
(5)
(6)
"Medicinal dosage form" means:
(a)
a tablet;
(b)
a capsule;
(c)
a concentrated oil;
(d)
a liquid
suspension
formulation
;
(e)
a transdermal preparation; or
(f)
a sublingual preparation.
(6)
(7)
"Physician" means an individual who is licensed under:
(a)
Title 58, Chapter 67, Utah Medical Practice Act
; or
(b)
Title 58, Chapter 68, Utah Osteopathic Medical Practice Act
.
(7)
(8)
"Terminal illness" means a condition of a patient that:
(a)
(i)
as determined by a physician:
(i)
(A)
is likely to pose a greater risk to the patient than the risk posed to the
patient by treatment with an investigational drug or investigational device; and
(ii)
(B)
will inevitably lead to the patient's death;
and
or
(ii)
as determined by a physician who is a board certified oncologist, is cancer; and
(b)
presents the patient, after the patient has explored conventional therapy options, with
no treatment option that is satisfactory or comparable to treatment with an
investigational drug or device.
Section 2. Section
58-85-107
is enacted to read:
58-85-107
. Repo
rt.
(1)
If a manufacturer of an investigational drug or investigational device provides an
investigational drug or investigational device to a patient located in the state to treat an
eligible illness, the manufacturer shall report
the

inform
ation described in Subsection
(2)

to the Health and Human Services Interim Committee before the November 1 that
follows the day the drug or device was provided to the patient.
(2)
The report shall include the following information:
(a)
the number of patients that received an investigational drug or investigational device
to treat an eligible illness;
(b)
each eligible illness being treated;
(c)
adverse outcomes likely attributable to the investigational drug or investigational
device; and
(d)
any other information the manufacturer dete
rmine
s

relevant.
(3)
Subsection
(1)
does not apply if the patient receiving the device or drug was part of
an
investigation
conducted under 21 C.F.R. Part 812 or a clinical investigation conducted
under 21 C.F.R. Part 312.
Section 3.
Effective Date.
This bill takes effect on
May 6, 2026
.
3-11-26 4:36 PM